Drug Profile
Research programme: anti-beta-amyloid antibodies - Centocor/ Johnson & Johnson
Alternative Names: JRF/hAb11/1Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Centocor; Johnson & Johnson Pharmaceutical Research & Development
- Class Monoclonal antibodies
- Mechanism of Action Amyloid beta-protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (Parenteral)
- 24 Jul 2006 Preclinical trials in Alzheimer's disease in USA (Intraperitoneal)